Pharma BD Deal Intelligence
Thermo Fisher bought capacity, not a drug: $1.7B cash for Brammer Bio's AAV/lentivirus viral vector CDMO platform, closed May 1, 2019, at a moment when manufacturing capacity was the bottleneck for gene therapy programs industry-wide.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Thermo Fisher to buy Brammer Bio for $1.7B, expanding gene therapy offerings and entering the viral vector CDMO space at a moment when capacity is the…
Thermo Fisher buys into gene therapy with $1.7B Brammer deal, joining Catalent (Paragon) in a wave of CDMO consolidation as biopharma scrambles for viral…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Thermo Fisher Scientific agreed to acquire Brammer Bio, a leading viral vector CDMO, for approximately $1.7B in cash. Adds AAV and lentivirus contract manufacturing capacity for gene therapy and gene-modified cell therapy programs. Closed May 1, 2019.
Assessment window: 5yr post-close.
$250M Brammer Bio projected 2019 revenue (Thermo Fisher disclosure)
Viral vector CDMO services provide outsourced manufacturing of AAV and lentivirus vectors used to deliver gene therapies and engineered cell therapies. Capacity has been a chronic bottleneck — by end-2018 only ~30 GMP viral vector manufacturers existed globally, and FDA/EMA approval timelines for gene therapies were increasingly gated on CMC and supply readiness rather than clinical data.
The 2019 viral vector CDMO landscape was rapidly consolidating around large life-science tools players. Brammer Bio (Cambridge MA, AAV+lentivirus) was widely considered the most attractive pure-play asset, with $250M projected 2019 revenue and growth above the 25% market rate. Thermo Fisher's $1.7B acquisition (March 2019) was followed weeks later by Catalent's $1.2B acquisition of Paragon Bioservices (April 2019), establishing a duopoly in scale viral vector outsourcing. Lonza, Oxford Biomedica, WuXi Advanced Therapies, Fujifilm Diosynth, and Cobra Biologics rounded out the competitive set. Analyst commentary from Evercore ISI's Ross Muken framed the deal as Thermo Fisher's playbook of bolt-on consolidation following the 2017 Patheon acquisition, positioning the company for the gene therapy approval wave (Luxturna had been approved 2017, Zolgensma was pending May 2019). The acquisition was viewed as strategically sound but priced at a premium reflecting scarcity of GMP capacity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Brammer Bio (this deal) | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2019 deals · Thermo Fisher Scientific Inc. deals · Gene Therapy deals